Phase I Trial of Z-Endoxifen in Adults With Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors

Trial Profile

Phase I Trial of Z-Endoxifen in Adults With Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 May 2017

At a glance

  • Drugs Endoxifen (Primary)
  • Indications Breast cancer; Endometrial cancer; Fallopian tube cancer; Fibroma; Ovarian cancer; Peritoneal cancer; Uterine cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Feb 2017 Planned End Date changed from 31 Oct 2017 to 31 Oct 2018.
    • 25 Feb 2017 Planned primary completion date changed from 31 Oct 2017 to 31 Oct 2018.
    • 02 Nov 2016 Planned End Date changed from 1 Oct 2016 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top